Cross-sectional study reveals specific metabolite signatures across kidney disease stages in type 2 diabetes, highlighting candidate biomarkers for monitoring severity.
Diabetic kidney disease (DKD) is commonly staged using albumin-to-creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR), yet complementary molecular markers are needed. We profiled urine and serum metabolites from 92 Korean participants (72 with type 2 diabetes and 20 healthy controls) using gas chromatography-tandem mass spectrometry (GC-MS/MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS). An exploratory restricted Boltzmann machine framework compared five DKD staging criteria and prioritized candidate metabolites; robustness was assessed against LASSO, linear support vector machine (SVM), and random forest using nested cross-validation. ACR-based staging showed the highest metabolomic discrimination. Urinary adenosine and 5′-methylthioadenosine decreased, whereas serum N2,N2-dimethylguanosine and cis -aconitic acid increased across ACR stages. Integration with a public renal tubular microarray dataset suggested NT5E as a cross-study network hub. These cross-sectional findings define candidate metabolite signatures associated with DKD severity and require external longitudinal validation before clinical translation.
No takes yet. Share an insight, caveat, or question.
Jung et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: